Thymosin Beta 4 (TB4) is a 43 amino acid, 5 kDa polypeptide that is an important mediator of cell proliferation, migration, and differentiation. Tb4 is regarded as the main G-actin sequestering peptide. It is found naturally in all tissues and cell types except red blood cells. Thymosin Beta 4 is angiogenic and can promote endothelial cell migration and adhesion, and angiogenesis. TB4 also accelerates wound healing and reduces inflammation.
Summary of beneficial effects of Thymosin Beta 4 (TB4) include:
- Differentiation of endothelial cells (blood and lymphatic vessels)
- Promotes the growth of new blood vessels – angiogenesis
- Keratinocyte migration
- Improves collagen deposition
- Decreases scar tissue formation
- Overall improved tissue repair
- Faster healing of wounds
- Helps in the repair of tendons and ligaments
- Improves flexibility of joints
- Prevents the formations of adhesions and fibrous bands in muscles, tendons, and ligaments
- Decreases inflammation in various tissue types
- Increases muscle growth
- Increases in endurance and strength
- Relaxes muscle spasm and improves muscle tone
- Repairs damaged heart tissue following a heart attack
- Healing of ulcers and lesions (including pressure, venous, stomach and intestinal ulcers)
- Promotes hair growth
- Protects and restores neurons after brain injury
- Protects brain neurons from autoimmune inflammation
1) 4-week protocol 2 vials: Reconstitution is with 4mLs of BAC water. Inject 100 units (1mL) 3.75 mg 2x per week.
2) 4-week protocol 1 vial: Reconstitution is with 4mLs of BAC water. Inject 100 units (1mL) 3.75mg 1x per week.
- Protocols are defined by prescription
- Do not dose concurrently for more than 3 months
- Cycle if needed long-term – 3 months on, 6 weeks off or 6 weeks on, 6 weeks off
Potential Side Effects and Studies:
- Thymosin Beta 4 peptide administered subcutaneously is reported safe and efficacious in recommended dosages.
- As with all injections, redness and pain at the site of injection may be present.
- Based on FDA recommendations and various guidance documents developed by the International Conference of Harmonization (ICH), 23 nonclinical studies have been performed to date that demonstrate the safety of Tb4 for its current and planned uses in man
**Be sure to follow directions as prescribed on the bottle when received.**
- Neurological Functional Recovery After Thymosin Beta4 Treatment in Mice with Experimental Auto Encephalomyelitis
- An unmet clinical need: roads to remyelination in MS
- Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases
- Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application
- Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system
- A new insight into thymosin β4, a promising therapeutic approach for neurodegenerative disorders
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
- Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke